• $913.00
    Market Cap
  • -99.75%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2023
12/31/2021
12/31/2020
Income Statement
Total Operating Revenue
97.4M
-6.82%
104.6M
+81.43%
57.6M
N/A
Cost of Revenue
51.5M
-6.57%
55.2M
+161.17%
21.1M
N/A
Gross Profit
45.9M
-7.09%
49.4M
+35.29%
36.5M
N/A
Sales and Marketing Expense
63.4M
+208.75%
20.5M
-11.38%
23.2M
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
5.6M
-16.21%
6.6M
-22.50%
8.6M
N/A
Total Operating Expenses
66.7M
+5.10%
63.5M
-8.13%
69.1M
N/A
Operating Profit
-20.8M
+47.79%
-14.1M
-56.74%
-32.6M
N/A
Interest Income
N/A
N/A
15,000
-80.52%
77,000
N/A
Interest Expense
-13.8M
+0.74%
-13.7M
-13.15%
-15.8M
N/A
Interest Income and Expense and Net
-13.8M
+0.85%
-13.7M
-12.82%
-15.7M
N/A
Total Nonoperating Income and Expense
-16.8M
-35,800.00%
47,000
-93.84%
763,000
N/A
Income before Taxes
-37.6M
+54.47%
-24.4M
-45.80%
-44.9M
N/A
Income Taxes
7.1M
-49.09%
13.9M
-7.43%
15.0M
N/A
Extraordinary Items
N/A
N/A
380,000
0.00%
380,000
N/A
Net Income
-91.6M
-339.23%
38.3M
+181.42%
-47.1M
N/A
Net Income from Continuing Operations Applicable to Common
-37.6M
+54.47%
-24.4M
-45.80%
-44.9M
N/A
Basic EPS and Net Income
N/A
N/A
-0.06
-33.33%
-0.09
N/A
Diluted EPS and Net Income
N/A
N/A
-0.06
-33.33%
-0.09
N/A
Basic Weighted Average Shares
649.7M
+9.93%
591.0M
+13.53%
520.6M
N/A
Diluted Weighted Average Shares
649.7M
+9.93%
591.0M
+13.53%
520.6M
N/A
Balance Sheet
Cash and Cash Equivalents
3.4M
-84.95%
22.6M
+19.27%
18.9M
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
3.4M
-84.95%
22.6M
+19.27%
18.9M
N/A
Total Current Assets
33.9M
-33.34%
50.9M
+13.72%
44.7M
N/A
Accumulated Depreciation
12.8M
+62.46%
7.9M
+30.87%
6.0M
N/A
Property and Plant and Equipment and Net
36.5M
-14.27%
42.6M
+26.82%
33.6M
N/A
Total Long-Term Assets
36.5M
-14.27%
42.6M
+26.82%
33.6M
N/A
Total Assets
264.0M
+3.29%
255.5M
+24.80%
204.8M
N/A
Income Taxes Payable
51.5M
+61.91%
31.8M
+76.45%
18.0M
N/A
Total Short-Term Debt
15.8M
-73.28%
59.2M
+16.02%
51.0M
N/A
Total Current Liabilities
104.0M
+112.95%
48.8M
+29.26%
37.8M
N/A
Total Long-Term Debt
11.1M
+546.69%
1.7M
-10.38%
1.9M
N/A
Total Long-Term Liabilities
158.8M
+43.65%
110.5M
+66.16%
66.5M
N/A
Total Liabilities
315.3M
+44.65%
218.0M
+34.11%
162.6M
N/A
Retained Earnings
-427.4M
+47.96%
-288.9M
+15.29%
-250.5M
N/A
Total Stockholders Equity
-51.5M
-237.22%
37.5M
-11.07%
42.2M
N/A
Total Shares Outstanding
669.5M
N/A
N/A
N/A
N/A
N/A
Cash Flow
Cash from Operating Activities
-1.8M
-131.78%
5.8M
+141.14%
-14.0M
N/A
Capital Expenditures
300,000
-97.84%
13.9M
-0.02%
13.9M
N/A
Cash from Investing Activities
-3.4M
-73.54%
-13.0M
-133.08%
39.3M
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
-5.5M
-150.97%
10.9M
+175.05%
-14.5M
N/A
Financials Ratio
Gross Margin
N/A
N/A
47.24%
-25.43%
63.35%
N/A
Operating Margin
N/A
N/A
-13.49%
-76.16%
-56.58%
N/A
Return on Assets
N/A
N/A
16.65%
+172.29%
-23.03%
N/A
Return on Equity
N/A
N/A
96.09%
+220.68%
-79.62%
N/A
Revenue Growth
N/A
N/A
81.43%
-4.39%
85.17%
N/A
Current Ratio
N/A
N/A
1.04
-12.02%
1.18
N/A
Cash Ratio
N/A
N/A
0.46
-7.72%
0.50
N/A
Debt-to-Equity Ratio
N/A
N/A
1.62
+29.39%
1.25
N/A
Debt-to-Assets Ratio
N/A
N/A
0.24
-7.81%
0.26
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow